ANDA 77473, held by Hospira. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77473 (Ondansetron Hydrochloride), held by Hospira, was first approved by FDA on Dec 26, 2006, with 6 approved supplements and 0 published complete response letters.
Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Nov 18, 2025 | Supplement 21Labeling · Standard review | Approved | None posted |
| Mar 15, 2022 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 1, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 1, 2021 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 24, 2013 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 24, 2013 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 26, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters